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background: There is growing evidence that high aldosterone (AL)exposure is associated with reduced survival in patients with cardiovascular 
diseases. Further, the potent cardiorenal actions of natriuretic peptides (NP) that include vasodilatation, natriuresis and diuresis offer an innovative 
therapeutic option in the management of hypertension and heart failure. We report the results of a preclinical study investigating the effect of 
LCZ696, a novel angiotensin receptor neprilysin(NEP) inhibitor providing simultaneous neprilysin inhibition and AT1-receptor blockade, on the 
dynamics of the renin and NP cascades.
Methods: Eighteen healthy beagle dogs were placed on a low-salt diet to activate the renin-angiotensin system. The effect of 10 days of treatment 
(p.o.,q.d.) with LCZ696 (15 and 45 mg/kg) was compared to placebo, valsartan (60 mg/kg) and benazepril (0.33 mg/kg), using a cross-over 
design. Biomarkers of the renin cascade and cGMP were measured in plasma on days 1, 5 and 10 of dosing and analyzed as a mean of the 3 days 
using random effect-repeated measures ANOVA.
results: Compared to placebo, benazepril modestly reduced AL (p=0.08). In contrast, valsartan, LCZ696 15 and 45 mg/kg decreased AL levels to a 
significant extent (-23%, -45% and -43%, respectively, p<0.05). The greatest reductions were observed in the LCZ696 groups, where LCZ696 15 mg/
kg at 2 hours reduced AL 2-fold lower than valsartan (p<0.05). Administration of LCZ696 at 45 mg/kg resulted in a 180% increase of cGMP relative 
to placebo (p<0.0001), which is consistent with enhanced NP action consecutive to NEP inhibition. Neither valsartan nor benazepril changed cGMP 
levels. In LCZ696 45 mg/kg treated dogs, an ~2.5-fold (1.8-3.7) increase from placebo was found for renin activity (p<0.0005), angiotensin I 
(p<0.005) and angiotensin II (p<0.05), reflecting a known compensatory up-regulation of the renin-angiotensin system to AT1-receptor blockade.
conclusion: The greater reduction of AL with LCZ696 over valsartan is consistent with the simultaneous blockade of the AT1-receptor and 
enhancement of the NP system. These results support further development of LCZ696 for the management of cardiovascular diseases.
